GlassScriptPhysician profile
David J Dicesar
NPI 1689837734
$255,168.93
in general payments reported to CMS, 2019-2025
44 companies · $52K in 2025
The $52K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $14K · 2021: $45K · 2022: $42K · 2023: $32K · 2024: $47K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $41K · Travel and Lodging: $14K · Food and Beverage: $8,218 · Consulting Fee: $175 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,873.44 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $41,173.00 |
| Travel and Lodging | $13,526.27 |
| Food and Beverage | $8,217.58 |
| Consulting Fee | $175.00 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $160,133.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $50,562.45 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $27,433.38 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $9,631.87 | 2019-2020 | |
| Ibsa Pharma INC. | $1,652.97 | 2020-2025 | Licart, Tirosint, Flector |
| Lilly USA, LLC | $824.20 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $627.09 | 2020-2025 | Prolia, Evenity, Tepezza |
| Medtronic, INC. | $455.28 | 2024-2025 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $358.72 | 2019-2024 | Synjardy, Tradjenta, Jardiance |
| Astrazeneca Pharmaceuticals LP | $329.69 | 2020-2024 | Farxiga |
| Abbott Laboratories | $281.74 | 2019-2025 | Freestyle Libre 3 |
| Ascendis Pharma Endocrinology INC | $251.85 | 2025 | Yorvipath |
| Novartis Pharmaceuticals Corporation | $239.96 | 2023-2024 | |
| Pfizer INC. | $231.47 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $198.44 | 2019-2025 | Strensiq |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $170.24 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $165.41 | 2021-2025 | |
| Corcept Therapeutics | $161.07 | 2023-2025 | Korlym |
| Mannkind Corporation | $152.88 | 2019-2025 | Afrezza |
| Xeris Pharmaceuticals, INC. | $130.64 | 2024-2025 | Recorlev |
| Recordati_rare_diseases_inc. | $109.21 | 2023-2025 | Isturisa, Signifor Lar |
| Beta Bionics, INC. | $108.32 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Abbvie INC. | $108.10 | 2023-2025 | Synthroid |
| Medtronic Minimed, INC. | $96.50 | 2019 | |
| Radius Health, INC. | $93.08 | 2019-2025 | |
| Amphastar Pharmaceuticals, INC. | $76.81 | 2024-2025 | |
| Genzyme Corporation | $72.00 | 2020 | |
| Amneal Pharmaceuticals LLC | $63.80 | 2025 | Unithroid |
| Sequel Med Tech, LLC | $60.25 | 2025 | Twiist |
| Insulet Corporation | $43.46 | 2024 | Omnipod |
| Ultragenyx Pharmaceutical INC. | $42.15 | 2024 | Crysvita |
| Amarin Pharma, INC. | $37.19 | 2019-2022 | |
| Madrigal Pharmaceuticals | $32.13 | 2025 | Rezdiffra |
| Glaxosmithkline, LLC. | $29.52 | 2019-2025 | Shingrix, Arexvy |
| Kyowa Kirin, INC. | $28.56 | 2025 | |
| Cequr Corporation | $25.53 | 2024-2025 | Cequr Simplicity |
| Almatica Pharma LLC | $25.32 | 2025 | Teriparatide |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Chiesi USA, INC. | $22.75 | 2025 | Mycapssa |
| Exact Sciences Corporation | $19.71 | 2025 | Cologuard Collection Kit |
| Tolmar, INC. | $19.06 | 2025 | Jatenzo |
| Biohaven Pharmaceutical Holding Company LTD. | $13.38 | 2022 | |
| Jazz Pharmaceuticals INC. | $13.09 | 2019 | |
| Merck Sharp & Dohme LLC | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dicesar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.